SCHEMBL5113359

SCHEMBL5113359

CCOC(=O)c1c(O)c2c(C)csc2n(Cc2ccccc2)c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 3/20 0.56
ERCC5 P28715 1/20 0.56
KDM4E B2RXH2 4/20 0.51
TSHR P16473 2/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
PDE1B Q01064 1/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP2 O95551 1/20 0.46
NSD2 O96028 1/20 0.46
PLCG1 P19174 1/20 0.46
PAX8 Q06710 1/20 0.46
ALDH1A1 P00352 5/20 0.46
MAPK1 P28482 1/20 0.46
POLB P06746 1/20 0.45
ATM Q13315 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5114638 0.90 KDM4E (0.50) FEN1ERCC5KDM4ETSHRLMNA
SCHEMBL27724198 0.88 ERCC5 (0.61) FEN1ERCC5TSHRLMNAMAPT
SCHEMBL4155322 0.81 KDM4E (0.58) FEN1ERCC5KDM4ETSHRLMNA
SCHEMBL1522548 0.80 KDM4E (0.59) FEN1KDM4ETSHRLMNAMAPT
SCHEMBL4517627 0.79 ALDH1A1 (0.51) FEN1ERCC5KDM4ETSHRLMNA
SCHEMBL4158509 0.77 FEN1 (0.67) FEN1ERCC5KDM4ETSHRMAPT
SCHEMBL5139475 0.77 HTT (0.47) FEN1ERCC5KDM4ELMNAALDH1A1
SCHEMBL5114645 0.77 KDM4E (0.55) KDM4ETSHRLMNAMAPTGAA
SCHEMBL1522936 0.76 KDM4E (0.81) KDM4ELMNAMAPTGAAPKM
SCHEMBL1959445 0.75 AR (0.57) KDM4ETSHRLMNAMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365200-B2 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS (US) 2008-04-29 US disclosed
US-7365200-B2 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS (US) 2008-04-29 US disclosed
US-7365200-B2 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS (US) 2008-04-29 US disclosed
EP-1861407-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-12-05 EP disclosed
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-08-02 US disclosed
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-08-02 US disclosed
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-08-02 US disclosed
US-20060229314-A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS 2006-10-12 US disclosed
WO-2006102191-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS MIF, MMP12, MSR1 FEN1 2495/4885ERCC5 4724/4885KDM4E 1648/4885
US-20060229314-A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors MIF, MMP12, MSR1 FEN1 2495/4885ERCC5 4724/4885KDM4E 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.